{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T23:40:19Z","timestamp":1738971619796,"version":"3.37.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T00:00:00Z","timestamp":1235692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p><jats:bold>Background and purpose:\u2002<\/jats:bold>Orthostatic hypotension has been observed when PDE 5 (cGMP\u2010specific phosphodiesterase type 5) inhibitors are co\u2010administered with \u03b1\u2010adrenoceptor antagonists. Here we assessed the pharmacokinetic and haemodynamic interactions between udenafil and tamsulosin in rats, as both drugs are metabolized via rat hepatic cytochrome P450 3A1\/2.<\/jats:p><jats:p><jats:bold>Experimental approach:\u2002<\/jats:bold>Interactions between the two drugs were evaluated in rats after simultaneous 1 or 15\u2003min i.v. infusion or after p.o. administration of udenafil (30\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>) and\/or tamsulosin (1\u2003mg\u00b7kg<jats:sup>\u22121<\/jats:sup>).<jats:italic>In vitro<\/jats:italic>metabolism of tamsulosin with udenafil was measured to obtain the inhibition constant (<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>) and [I]\/<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>ratio of udenafil.<\/jats:p><jats:p><jats:bold>Key results:\u2002<\/jats:bold>The total area under the plasma concentration\u2013time curve from time zero to time infinity (AUC)s (or AUC<jats:sub>0\u20134h<\/jats:sub>) of tamsulosin were significantly greater after 15\u2003min of i.v. infusion or after oral administration with udenafil, compared with tamsulosin alone. The hepatic first\u2010pass metabolism of tamsulosin was inhibited by udenafil, and the inhibition<jats:italic>in vitro<\/jats:italic>was in a non\u2010competitive mode. The arterial systolic blood pressure was significantly lower at 5, 10 and 60\u2003min after oral co\u2010administration of the drugs.<\/jats:p><jats:p><jats:bold>Conclusions and implications:\u2002<\/jats:bold>The significantly greater AUC of tamsulosin after i.v. and p.o. administration of both drugs may be attributable to non\u2010competitive inhibition of cytochrome P450 3A1\/2\u2010mediated hepatic tamsulosin metabolism by udenafil. The inhibition was also observed in human liver S9 fractions, suggesting that a reassessment of the oral dosage of tamsulosin is necessary when udenafil and tamsulosin are co\u2010administered to patients with benign prostatic hyperplasia.<\/jats:p>","DOI":"10.1111\/j.1476-5381.2008.00099.x","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T15:28:17Z","timestamp":1235748497000},"page":"1009-1018","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interaction between udenafil and tamsulosin in rats: non\u2010competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1\/2"],"prefix":"10.1111","volume":"156","author":[{"given":"HE","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SK","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DC","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YG","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MG","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E508"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062108"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20744"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707680"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj0550170"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/js960303k"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250400010898"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02980254"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/004982598238985"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03107.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.453"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2005.030.07.918084"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.07.011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000142687.75577.e4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01318a036"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-9556(25)05728-9","article-title":"Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species","volume":"3","author":"Litterst CL","year":"1975","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.18.252"},{"key":"e_1_2_8_20_1","first-page":"205","article-title":"Effects of adrenoceptor blocking drugs on cardiovascular responsiveness to passive orthostasis: a placebo\u2010controlled double\u2010blind study","volume":"55","author":"Nieminen T","year":"2005","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.11.002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707192"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.498"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.238"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10482"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259609046714"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.628"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2008.00099.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2008.00099.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T22:59:13Z","timestamp":1738969153000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2008.00099.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1476-5381.2008.00099.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00099.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"type":"print","value":"0007-1188"},{"type":"electronic","value":"1476-5381"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"2009-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}